E-Newsletter - Summer 2017

Alliance INVESTIGATORS at asco 2017

 

 

 

 

 

 

 

 

 


The 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO) convened in Chicago June 2-6, bringing together more than 30,000 oncology professionals from around the world. The theme, "Making a Difference in Cancer Care with You," encompassed studies spanning the spectrum of cancer prevention and care, from immunotherapy and precision medicine to survivorship.  

ASCO attendees learned from leading-edge scientific presentations, including papers and talks from Alliance researchers, as well as thousands of scientific abstracts and research news developments. Alliance scientists presented more than 25 studies, sharing the latest findings on breast cancer, brain cancer, hematologic cancers, and gastric cancer, along with cancer control research, at this year's meeting. The Alliance was well-represented with dozens of researchers participating on panels, discussing new research and giving poster presentations.
 
Here's a snapshot of studies that Alliance researchers presented this year:
 
Breast Cancer
Evaluating the addition of bevacizumab (Bev) to endocrine therapy as first-line treatment for hormone-receptor positive (HR+)/HER2-negative advanced breast cancer (ABC): Pooled-analysis from the LEA (GEICAM/2006-11_GBG51) and CALGB 40503 (Alliance) trials
Presenter: Miguel Martin
Study #: CALGB 40503
J Clin Oncol 35, 2017 (suppl; abstr 1012) | Poster

Updated results from the phase III ALTTO trial (BIG 2-06; NCCTG (Alliance) N063D) comparing one year of anti-HER2 therapy with lapatinib alone (L), trastuzumab alone (T), their sequence (T→L) or their combination (L+T) in the adjuvant treatment of HER2-positive early breast cancer
Presenter: Alvaro Moreno-Aspitia
Study #: NCCTG N063D
J Clin Oncol 35, 2017 (suppl; abstr 502) | Oral
 
Central Nervous System Tumors
NCCTG N1174: Phase I/comp arative randomized phase (Ph) II trial of TRC105 plus bevacizumab versus bevacizumab in recurrent glioblastoma (GBM) (Alliance)
Presenter: Evanthia Galanis
Study #: NCCTG N1174
J Clin Oncol 35, 2017 (suppl; abstr 2023) | Poster
 
Chronic Lymphocytic Leukemia (CLL)
A genetic risk-stratified, randomized phase 2 intergroup study of fludarabine/antibody combinations in symptomatic, untreated chronic lymphocytic leukemia (CLL): Results from Cancer and Leukemia Group B (CALGB) 10404 (Alliance)
Presenter: Amy S. Ruppert
Study #: CALGB 10404
J Clin Oncol 35, 2017 (suppl; abstr 7503) | Oral
 
Gastrointestinal Cancer
Prospective pooled analysis of six phase III trials investigating duration of adjuvant (adjuv) oxaliplatin-based therapy (3 vs 6 months) for patients (pts) with stage III colon cancer (CC): The IDEA (International Duration Evaluation of Adjuvant chemotherapy) collaboration
Presenter: Qian Shi
Study #: IDEA/CALGB 8 0702
J Clin Oncol 35, 2017 (suppl; abstr LBA1) | Oral

 
Nut consumption and survival in stage III colon cancer patients: Results from CALGB 89803 (Alliance)
Presenter: Temidayo Fadelu
Study #: CALGB 89803
J Clin Oncol 35, 2017 (suppl; abstr 3517) | Poster
Learn more about the results
 
Statistical modeling of CALGB 80405 (Alliance) to identify influential factors in metastatic colorectal cancer (CRC) dependent on primary tumor side
Presenter: David Swanson
Study #: CALGB 80405
J Clin Oncol 35, 2017 (suppl; abstr 3528) | Poster

Impact of consensus molecular subtyping (CMS) on overall survival (OS) and progression free survival (PFS) in patients (pts) with metastatic colorectal cancer (mCRC): Analysis of CAL GB/SWOG 80405 (Alliance)
Presenter: Heinz-Josef Lenz
Study #: CALGB 80405
J Clin Oncol 35, 2017 (suppl; abstr 3511) | Clinical Science Symposium
 
Primary (1°) tumor location as an independent prognostic marker from molecular features for overall survival (OS) in patients (pts) with metastatic colorectal cancer (mCRC): Analysis of CALGB / SWOG 80405 (Alliance)
Presenter: Alan Venook
Study #: CALGB 80405
J Clin Oncol 35, 2017 (suppl; abstr 3503) | Oral
 
Somatic DNA mutations, MSI status, mutational load (ML): Association with overall survival (OS) in patients (pts) with metastatic colorectal cancer (mCRC) of CALGB/SWOG 80405 (Alliance)
Presenter: Federico Innocenti
Study #: CALGB 80405
J Clin Oncol 35, 2017 (suppl; abstr 3504) | Oral
 
Association of immune markers and Immunoscore with survival of stage III colon carcinoma (CC) patients (pts) treated with adjuvant FOLFOX: NCCTG N0147 (Alliance)
Presenter: Frank A. Sinicrope
Study #: NCCTG N0147
J Clin Oncol 35, 2017 (suppl; abstr 3579) | Poster
 
Genetic correlates of therapeutic toxicities of stage III colon carcinoma patients treated with adjuvant FOLFOX+/-cetuximab (NCCTG N0147, Alliance)
Presenter: Polly A. Newcomb
Study #: NCCTG N0147
Clin Oncol 35, 2017 (suppl; abstr 3604) | Poster
 
Analysis of serum v itamin D levels and prognosis in stage III colon carcinoma patients treated with adjuvant FOLFOX+/- cetuximab chemotherapy: NCCTG N0147 (Alliance)
Presenter: Frank A. Sinicrope
Study #: NCCTG N0147
J Clin Oncol 35, 2017 (suppl; abstr 3516) | Poster
 
Randomized trial of FOLFOX alone or combined with atezolizumab as adjuvant therapy for patients with stage III colon cancer and deficient DNA mismatch repair or microsatellite instability (ATOMIC, Alliance A021502)
Presenter: Frank A. Sinicrope
Study #: Alliance A021502
J Clin Oncol 35, 2017 (suppl; abstr TPS3630) | Poster
 
Alliance for Clinical Trials in Oncology trial A021501: Preoperative extended chemotherapy vs. chemotherapy plus hypofractionated radiation therapy for borderline resectable adenocarcinoma of the head of the pancreas
Presenter: Matthew H. G. Katz
Study #: Alliance A021501
J Clin Oncol 35, 2017 (suppl; abstr TPS4151) | Poster
 
Genitourinary Cancer  
Serum androgens and survival in  metastatic castration resistant prostate cancer (mCRPC) patients treated with docetaxel and prednisone: Results from CALGB 90401 (Alliance)
Presenter: Charles J. Ryan
Study #: CALGB 90401
J Clin Oncol 35, 2017 (suppl; abstr 5067) | Poster

Association of on-treatment plasma HGF levels with overall survival (OS) in patients (pts) with advanced renal cell carcinoma (RCC) treated with interferon alpha (INF) +/- bevacizumab (BEV): Results from CALGB 90206 (Alliance)
Presenter: Daniel J. George
Study #: CALGB 90206
J Clin Oncol 35, 2017 (suppl; abstr 4522) | Poster
 
Health Services Research, Clinical Informatics and Quality of Care
Understanding the non-curative potential of palliative chemotherapy: Do patients hear what they want to hear?
Presenter: Andrea Catherine Enzinger
Study #: NCT02282722
J Clin Oncol 35, 2017 (suppl; abstr 6575) | Poster
 
Multiple Myeloma
CALGB/ECOG 100104 (Alliance) study: Lenalidomide (LEN) vs placebo (PBO) maintenance (maint) after stem cell transplant (SCT) for patients (pts) with multiple myeloma-Overall survival (OS) and progression-free survival (PFS) adjusted for treatment (tx) crossover (XO)
Presenter: Philip L. McCarthy
Study #: CALGB 100104
Poster Session (Board #363) | Poster
 
Patient and Survivor Care
American Cancer Society (ACS) nutrition and physical activity guidelines after colon cancer diagnosis and disease-free (DFS), recurrence-free (RFS), and overall survival (OS) in CALGB 89803 (Alliance)
Presenter: Erin Van Blarigan
Study #: CALGB 89803
J Clin Oncol 35, 2017 (suppl; abstr 10006) | Poster
Learn more about the results
 
Comparative nocebo effects in older patients enrolled in cancer therapeutic trials: Observations from a 446-patient cohort-NCCTG 97-24-51 and ACOSOG Z9001 (Alliance A151602)
Presenter: Jennifer Le-Rademacher and Jared C. Foster
Study #: Alliance A151602, ACOSOG Z9001, NCCTG 97-24-51
J Clin Oncol 35, 2017 (suppl; abstr e21545)
 
Sarcoma
A multi-center phase II study of nivolumab +/- ipilimumab for patients with metastatic sarcoma (Alliance A091401)
Presenter: Sandra P. D'Angelo
Study #: Alliance A091401
J Clin Oncol 35, 2017 (suppl; abstr 11007) | Oral
  

ALLIANCE FOUNDATION TRIALS (AFT)

Health Services Research, Clinical Informatics and Quality of Care
Comparison of comorbidity measures to predict postoperative lung cancer survival in the National Cancer Database (AFT-03)
Presenter: Melisa L. Wong
Study #: AFT-03
J Clin Oncol 35, 2017 (suppl; abstr 6519) | Poster
 
Asymptomatic distant recurrence detection and survival in early stage breast cancer: A nationally representative study
Presenter: Jessica R. Schumacher
Study #: PCORI AFT-01
J Clin Oncol 35, 2017 (suppl; abstr 6520) | Poster
 
Lung Cancer
Tolerability of veliparib (V) in combination with carboplatin (C)/paclitaxel (P): Based chemoradiotherapy (CRT) in subjects with stage III non-small cell lung cancer (NSCLC)
Presenter: David E. Kozono
J Clin Oncol 35, 2017 (suppl; abstr 8546) | Poster
 
Patient and Survivor Care
Impact of intensity of post-treatment surveillance on survival in colorectal cancer
Presenter: Rebecca A Snyder
Study #: PCORI AFT 02
J Clin Oncol 35, 2017 (suppl; abstr 10016) | Poster

 

For other articles in the Summer issue of the Alliance E-News newsletter, see below.